Navigating Complexity in Pulmonary Trials: Using Adaptive Trial Designs

If you’re a Sponsor working in Idiopathic Pulmonary Fibrosis (IPF), Acute Respiratory Distress Syndrome (ARDS), or Cystic Fibrosis (CF), you know how unpredictable these diseases can be. Adaptive designs offer the flexibility to respond to emerging data, helping you make smarter decisions faster.

Using Adaptive Trial Designs in Pulmonary Indications

Adaptive designs allow for pre-specified changes to trial parameters based on interim data. These changes, like adjusting sample size or dropping underperforming arms, are proactively planned and statistically controlled.

Common types include:

• Seamless Phase 2/3 designs
• Response-adaptive randomization
• Sample size re-estimation
• Drop-the-loser designs

Within pulmonary trials, sponsors often face challenges including variable progression, high-risk populations, and rare subtypes. By implanting adaptive designs, Sponsors can respond to these challenges in real time.

Examples of Adaptive Design in Pulmonary Trials

Seamless Design in IPF – The INMARK Trial

The INMARK trial used a seamless Phase 2/3 design to evaluate nintedanib in IPF. Early biomarker data helped drop ineffective doses and expand promising ones, saving time and resources.

Response-Adaptive Randomization in ARDS

In ARDS trials, response-adaptive randomization has been used to allocate more patients to effective ventilatory strategies. This approach improves outcomes and ethical balance.

Genotype-Driven Flexibility in CF

CF trials targeting specific CFTR mutations benefit from adaptive enrollment strategies. Sponsors can expand cohorts based on early efficacy signals, improving trial efficiency.

Regulatory Support and Considerations

Both FDA and EMA support adaptive designs, especially in rare or high-risk diseases. Sponsors must pre-specify adaptation rules, conduct simulations, and maintain transparent communication.

Conclusion

Adaptive designs offer Sponsors a powerful way to navigate the complexity of pulmonary trials.

As a CRO with expertise in adaptive methodologies, PharPoint can support biopharmaceutical companies with:

• Simulation-tested protocol design
• Real-time data analytics for interim decisions
• Regulatory alignment and documentation
• Site training and operational readiness

For more information on how we can support your upcoming pulmonary trial, reach out to our team.